<DOC>
	<DOCNO>NCT00004378</DOCNO>
	<brief_summary>OBJECTIVES : I. Ascertain whether stem cell transplantation ( SCT ) effective method miss dysfunctional enzyme replace patient various inborn error metabolism . II . Determine whether clinical manifestation specific disease may arrest reversed treatment .</brief_summary>
	<brief_title>Stem Cell Transplantation ( SCT ) Genetic Diseases</brief_title>
	<detailed_description>PROTOCOL OUTLINE : Patients receive either cyclophosphamide high dose total body irradiation ( TBI ) busulfan cyclophosphamide . Cyclophosphamide IV give day -5 -4 TBI day -2 , -1 , 0 . Busulfan give orally every 6 hour day -9 -6 cyclophosphamide IV day -5 -2 . Patients rest day -1 . Patients receive bone marrow infusion day 0 . For GVHD prophylaxis , patient receive methotrexate day 1 , day 3 , 6 , 11 . Cyclosporine IV begin day -2 12 hour , follow continuous infusion 21 day . Then , oral dos cyclosporine give every 12 hour patient tolerate oral feeding . Cyclosporine continue 6 month posttransplant , taper 10 % per week stop . Patients receive genotypically HLA nonidentical stem cell undergo additional GVHD prophylaxis methylprednisolone ( IV PO ) equivalent every 12 hour day 3 day 100 . Dose tapered tolerated 1 month . Patients receive cord blood stem cell receive methylprednisolone instead methotrexate GHVD prophylaxis . Methylprednisolone give 3 time daily begin day 5 continue day 17 . Then , methylprednisolone taper 10 % per week clinically tolerate . To accelerate engraftment , patient receive filgrastim IM daily begin day +1 continue ANC equal 5000 .</detailed_description>
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Thrombocytopenia</mesh_term>
	<mesh_term>Thalassemia</mesh_term>
	<mesh_term>Fanconi Anemia</mesh_term>
	<mesh_term>Fanconi Syndrome</mesh_term>
	<mesh_term>beta-Thalassemia</mesh_term>
	<mesh_term>Metabolism , Inborn Errors</mesh_term>
	<mesh_term>Red-Cell Aplasia , Pure</mesh_term>
	<mesh_term>Leukodystrophy , Metachromatic</mesh_term>
	<criteria>PROTOCOL ENTRY CRITERIA : Disease Characteristics Hereditary enzymopathies , : Metachromatic leukodystrophy Congenital Immunodeficiencies Heritable hematologic disorder , : Thalassemia major Refractory DiamondBlackfan anemia Fanconi anemia Amegakaryocytic thrombocytopenia Patient Characteristics Age : Under 18 Other : SCT perform use histocompatible related donor , unrelated donor , unrelated cord blood donor Haploidentical donor accept patient severe congenital immunodeficiency</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>April 2002</verification_date>
	<keyword>Fanconi 's anemia</keyword>
	<keyword>amegakaryocytic thrombocytopenia</keyword>
	<keyword>aplastic anemia</keyword>
	<keyword>congenital pure red cell aplasia</keyword>
	<keyword>genetic disease dysmorphic syndrome</keyword>
	<keyword>hematologic disorder</keyword>
	<keyword>inborn error metabolism</keyword>
	<keyword>metachromatic leukodystrophy</keyword>
	<keyword>pure red cell aplasia</keyword>
	<keyword>rare disease</keyword>
	<keyword>sphingolipidoses</keyword>
	<keyword>thalassemia major</keyword>
</DOC>